Cary Street Partners’s GSK GSK Stock Holding History

Cary Street Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$315K	Buy	6,008 +98	+2%	+$5.18K	0.01%	793
2026 Q1	$326K	Hold	5,910	–	–	0.01%	693
2025 Q4	$290K	Buy	5,910 +53	+0.9%	+$2.47K	0.01%	737
2025 Q3	$253K	Sell	5,857 -1,064	-15%	-$41.6K	0.01%	727
2025 Q2	$266K	Buy	6,921 +1,306	+23%	+$49.9K	0.01%	690
2025 Q1	$218K	Sell	5,615 -1,116	-17%	-$40.9K	0.01%	723
2024 Q4	$228K	Buy	+6,731	New	+$242K	0.01%	685

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Cary Street Partners's GSK Position: Q2 2026 in Review

Cary Street Partners increased its GSK (GSK) stake by 1.7% in Q2 2026, buying an estimated $5.18K and bringing the position to 6,008 shares worth $315K. The position accounts for 0.01% of the portfolio, ranked #793.

Cary Street Partners first reported a position in GSK in Q4 2024 and has held it in 7 quarters since. The position peaked at $326K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Cary Street Partners held 6,008 shares of GSK worth $315K as of Q2 2026.
Cary Street Partners bought 98 GSK shares in Q2 2026, an estimated $5.18K.
GSK made up 0.01% of Cary Street Partners's portfolio in Q2 2026, its #793 holding.
Cary Street Partners first reported a position in GSK in Q4 2024 and has held it in 7 quarters since.
Cary Street Partners's GSK position peaked at $326K in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.